Exact Sciences announces its Oncodetect MRD test receives Medicar coverage

Exact Sciences (EXAS) announced that its Oncodetect molecular residual disease, or MRD, test has received Medicare coverage through the Centers for Medicare & Medicaid Services’, or CMS, Molecular Diagnostic Services Program, or MolDX, for serial use in patients with stage II, III and resectable stage IV colorectal cancer, or CRC, in the adjuvant and recurrence monitoring settings over a five-year period. The final LCD can be found here, and the billing and coding article here, from CMS. This marks a significant milestone in the company’s mission to transform cancer treatment through earlier detection and more personalized care. Medicare coverage for colorectal cancer is a step forward to address the more than three million Americans eligible for MRD testing across multiple solid tumors. The Oncodetect test is supported by robust clinical validation studies, including Beta-CORRECT which confirms the test’s prognostic power across stages II-IV CRC3, and Alpha-CORRECT, one of the longest-followed MRD cohorts for CRC recurrence. Its integration with the ExactNexus technology platform enables seamless ordering alongside other Exact Sciences Precision Oncology solutions.